サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1109254

世界のIgA腎症治療薬市場：考察と予測 (2028年まで)

Global IgA Nephropathy Drugs Market Insights, Forecast to 2028
出版日: | 発行: QYResearch | ページ情報: 英文 86 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
世界のIgA腎症治療薬市場：考察と予測 (2028年まで)
出版日: 2022年08月04日
発行: QYResearch
ページ情報: 英文 86 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、IgA腎症治療薬 (IgA Nephropathy Drugs) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポート概要

  • 調査範囲
  • 市場分析：タイプ別
    • 世界のIgA腎症治療薬の市場規模成長率：タイプ別, 2017 VS 2021 VS 2028
    • Phase I
    • Phase II
    • Phase III
  • 市場：アプリケーション別
    • 世界のIgA腎症治療薬の市場規模成長率：アプリケーション別, 2017 VS 2021 VS 2028
    • Clinical Treatment
    • Drug Experiment
  • 調査目的
  • 対象期間

第2章 世界の市場成長トレンド

  • 世界のIgA腎症治療薬の市場展望 (2017-2028)
  • IgA腎症治療薬の市場成長トレンド：地域別
    • IgA腎症治療薬 市場規模：地域別: 2017 VS 2021 VS 2028
    • IgA腎症治療薬の市場規模実績：地域別 (2017-2022)
    • IgA腎症治療薬の市場規模予測：地域別 (2023-2028)
  • IgA腎症治療薬 市場動向
    • IgA腎症治療薬 業界動向
    • IgA腎症治療薬 市場の促進要因
    • IgA腎症治療薬 市場の課題
    • IgA腎症治療薬 市場の抑制要因

第3章 競合情勢：主要企業別

  • 世界のIgA腎症治療薬の上位企業：収益別
    • 世界のIgA腎症治療薬の上位企業：収益別 (2017-2022)
    • 世界のIgA腎症治療薬の収益シェア：企業別 (2017-2022)
  • 世界のIgA腎症治療薬の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 企業ランキング：IgA腎症治療薬の収益
  • 世界のIgA腎症治療薬 市場集中度
    • 世界のIgA腎症治療薬 市場集中度 (CR5 and HHI)
    • 世界の上位10・上位5企業： IgA腎症治療薬の収益 2021
  • IgA腎症治療薬の主要企業の本社および事業エリア
  • 主要企業 IgA腎症治療薬の製品ソリューションおよびサービス
  • 市場参入時期： IgA腎症治療薬 市場
  • M&A, 拡張計画

第4章 IgA腎症治療薬 内訳データ：タイプ別

  • 世界のIgA腎症治療薬の市場規模実績：タイプ別 (2017-2022)
  • 世界のIgA腎症治療薬の市場規模予測：タイプ別 (2023-2028)

第5章 IgA腎症治療薬 内訳データ：アプリケーション別

  • 世界のIgA腎症治療薬の市場規模実績：アプリケーション別 (2017-2022)
  • 世界のIgA腎症治療薬の市場規模予測：アプリケーション別 (2023-2028)

第6章 北米

  • 北米のIgA腎症治療薬 市場規模 (2017-2028)
  • 北米のIgA腎症治療薬 市場規模：タイプ別
    • 北米のIgA腎症治療薬 市場規模：タイプ別 (2017-2022)
    • 北米のIgA腎症治療薬 市場規模：タイプ別 (2023-2028)
    • 北米のIgA腎症治療薬の市場シェア：タイプ別 (2017-2028)
  • 北米のIgA腎症治療薬 市場規模：アプリケーション別
    • 北米のIgA腎症治療薬 市場規模：アプリケーション別 (2017-2022)
    • 北米のIgA腎症治療薬 市場規模：アプリケーション別 (2023-2028)
    • 北米のIgA腎症治療薬の市場シェア：アプリケーション別 (2017-2028)
  • 北米のIgA腎症治療薬 市場規模：国別
    • 北米のIgA腎症治療薬 市場規模：国別 (2017-2022)
    • 北米のIgA腎症治療薬 市場規模：国別 (2023-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州のIgA腎症治療薬 市場規模 (2017-2028)
  • 欧州のIgA腎症治療薬 市場規模：タイプ別
    • 欧州のIgA腎症治療薬 市場規模：タイプ別 (2017-2022)
    • 欧州のIgA腎症治療薬 市場規模：タイプ別 (2023-2028)
    • 欧州のIgA腎症治療薬の市場シェア：タイプ別 (2017-2028)
  • 欧州のIgA腎症治療薬 市場規模：アプリケーション別
    • 欧州のIgA腎症治療薬 市場規模：アプリケーション別 (2017-2022)
    • 欧州のIgA腎症治療薬 市場規模：アプリケーション別 (2023-2028)
    • 欧州のIgA腎症治療薬の市場シェア：アプリケーション別 (2017-2028)
  • 欧州のIgA腎症治療薬 市場規模：国別
    • 欧州のIgA腎症治療薬 市場規模：国別 (2017-2022)
    • 欧州のIgA腎症治療薬 市場規模：国別 (2023-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • 北欧

第8章 アジア太平洋地域

  • アジア太平洋地域 IgA腎症治療薬 市場規模 (2017-2028)
  • アジア太平洋地域 IgA腎症治療薬 市場規模：タイプ別
    • アジア太平洋地域 IgA腎症治療薬 市場規模：タイプ別 (2017-2022)
    • アジア太平洋地域 IgA腎症治療薬 市場規模：タイプ別 (2023-2028)
    • アジア太平洋地域 IgA腎症治療薬の市場シェア：タイプ別 (2017-2028)
  • アジア太平洋地域 IgA腎症治療薬 市場規模：アプリケーション別
    • アジア太平洋地域 IgA腎症治療薬 市場規模：アプリケーション別 (2017-2022)
    • アジア太平洋地域 IgA腎症治療薬 市場規模：アプリケーション別 (2023-2028)
    • アジア太平洋地域 IgA腎症治療薬の市場シェア：アプリケーション別 (2017-2028)
  • アジア太平洋地域 IgA腎症治療薬 市場規模：地域別
    • アジア太平洋地域 IgA腎症治療薬 市場規模：地域別 (2017-2022)
    • アジア太平洋地域 IgA腎症治療薬 市場規模：地域別 (2023-2028)
    • 中国
    • 日本
    • 韓国
    • 東南アジア
    • インド
    • オーストラリア

第9章 ラテンアメリカ

  • ラテンアメリカのIgA腎症治療薬 市場規模 (2017-2028)
  • ラテンアメリカのIgA腎症治療薬 市場規模：タイプ別
    • ラテンアメリカのIgA腎症治療薬 市場規模：タイプ別 (2017-2022)
    • ラテンアメリカのIgA腎症治療薬 市場規模：タイプ別 (2023-2028)
    • ラテンアメリカのIgA腎症治療薬の市場シェア：タイプ別 (2017-2028)
  • ラテンアメリカのIgA腎症治療薬 市場規模：アプリケーション別
    • ラテンアメリカのIgA腎症治療薬 市場規模：アプリケーション別 (2017-2022)
    • ラテンアメリカのIgA腎症治療薬 市場規模：アプリケーション別 (2023-2028)
    • ラテンアメリカのIgA腎症治療薬の市場シェア：アプリケーション別 (2017-2028)
  • ラテンアメリカのIgA腎症治療薬 市場規模：国別
    • ラテンアメリカのIgA腎症治療薬 市場規模：国別 (2017-2022)
    • ラテンアメリカのIgA腎症治療薬 市場規模：国別 (2023-2028)
    • メキシコ
    • ブラジル

第10章 中東・アフリカ

  • 中東・アフリカのIgA腎症治療薬 市場規模 (2017-2028)
  • 中東・アフリカのIgA腎症治療薬 市場規模：タイプ別
    • 中東・アフリカのIgA腎症治療薬 市場規模：タイプ別 (2017-2022)
    • 中東・アフリカのIgA腎症治療薬 市場規模：タイプ別 (2023-2028)
    • 中東・アフリカのIgA腎症治療薬の市場シェア：タイプ別 (2017-2028)
  • 中東・アフリカのIgA腎症治療薬 市場規模：アプリケーション別
    • 中東・アフリカのIgA腎症治療薬 市場規模：アプリケーション別 (2017-2022)
    • 中東・アフリカのIgA腎症治療薬 市場規模：アプリケーション別 (2023-2028)
    • 中東・アフリカのIgA腎症治療薬の市場シェア：アプリケーション別 (2017-2028)
  • 中東・アフリカのIgA腎症治療薬 市場規模：国別
    • 中東・アフリカのIgA腎症治療薬 市場規模：国別 (2017-2022)
    • 中東・アフリカのIgA腎症治療薬 市場規模：国別 (2023-2028)
    • トルコ
    • サウジアラビア
    • UAE

第11章 主要企業のプロファイル

  • Calliditas Therapeutics
  • Travere Therapeutics
  • Omeros Corporation
  • Novartis International
  • Chinook Therapeutics
  • Vera Therapeutics
  • Otsuka Pharmaceutical

第12章 アナリストによる分析/結論

第13章 付録

図表

List of Tables

  • Table 1. Global IgA Nephropathy Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
  • Table 2. Key Players of Phase I
  • Table 3. Key Players of Phase II
  • Table 4. Key Players of Phase III
  • Table 5. Global IgA Nephropathy Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
  • Table 6. Global IgA Nephropathy Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
  • Table 7. Global IgA Nephropathy Drugs Market Size by Region (2017-2022) & (US$ Million)
  • Table 8. Global IgA Nephropathy Drugs Market Share by Region (2017-2022)
  • Table 9. Global IgA Nephropathy Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
  • Table 10. Global IgA Nephropathy Drugs Market Share by Region (2023-2028)
  • Table 11. IgA Nephropathy Drugs Market Trends
  • Table 12. IgA Nephropathy Drugs Market Drivers
  • Table 13. IgA Nephropathy Drugs Market Challenges
  • Table 14. IgA Nephropathy Drugs Market Restraints
  • Table 15. Global IgA Nephropathy Drugs Revenue by Players (2017-2022) & (US$ Million)
  • Table 16. Global IgA Nephropathy Drugs Revenue Share by Players (2017-2022)
  • Table 17. Global Top IgA Nephropathy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IgA Nephropathy Drugs as of 2021)
  • Table 18. Ranking of Global Top IgA Nephropathy Drugs Companies by Revenue (US$ Million) in 2021
  • Table 19. Global 5 Largest Players Market Share by IgA Nephropathy Drugs Revenue (CR5 and HHI) & (2017-2022)
  • Table 20. Key Players Headquarters and Area Served
  • Table 21. Key Players IgA Nephropathy Drugs Product Solution and Service
  • Table 22. Date of Enter into IgA Nephropathy Drugs Market
  • Table 23. Mergers & Acquisitions, Expansion Plans
  • Table 24. Global IgA Nephropathy Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 25. Global IgA Nephropathy Drugs Revenue Market Share by Type (2017-2022)
  • Table 26. Global IgA Nephropathy Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
  • Table 27. Global IgA Nephropathy Drugs Revenue Market Share by Type (2023-2028)
  • Table 28. Global IgA Nephropathy Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 29. Global IgA Nephropathy Drugs Revenue Share by Application (2017-2022)
  • Table 30. Global IgA Nephropathy Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
  • Table 31. Global IgA Nephropathy Drugs Revenue Share by Application (2023-2028)
  • Table 32. North America IgA Nephropathy Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 33. North America IgA Nephropathy Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 34. North America IgA Nephropathy Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 35. North America IgA Nephropathy Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 36. North America IgA Nephropathy Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 37. North America IgA Nephropathy Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 38. Europe IgA Nephropathy Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 39. Europe IgA Nephropathy Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 40. Europe IgA Nephropathy Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 41. Europe IgA Nephropathy Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 42. Europe IgA Nephropathy Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 43. Europe IgA Nephropathy Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 44. Asia Pacific IgA Nephropathy Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 45. Asia Pacific IgA Nephropathy Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 46. Asia Pacific IgA Nephropathy Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 47. Asia Pacific IgA Nephropathy Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 48. Asia Pacific IgA Nephropathy Drugs Market Size by Region (2017-2022) & (US$ Million)
  • Table 49. Asia Pacific IgA Nephropathy Drugs Market Size by Region (2023-2028) & (US$ Million)
  • Table 50. Latin America IgA Nephropathy Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 51. Latin America IgA Nephropathy Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 52. Latin America IgA Nephropathy Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 53. Latin America IgA Nephropathy Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 54. Latin America IgA Nephropathy Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 55. Latin America IgA Nephropathy Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 56. Middle East and Africa IgA Nephropathy Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 57. Middle East and Africa IgA Nephropathy Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 58. Middle East and Africa IgA Nephropathy Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 59. Middle East and Africa IgA Nephropathy Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 60. Middle East and Africa IgA Nephropathy Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 61. Middle East and Africa IgA Nephropathy Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 62. Calliditas Therapeutics Company Details
  • Table 63. Calliditas Therapeutics Business Overview
  • Table 64. Calliditas Therapeutics IgA Nephropathy Drugs Product
  • Table 65. Calliditas Therapeutics Revenue in IgA Nephropathy Drugs Business (2017-2022) & (US$ Million)
  • Table 66. Calliditas Therapeutics Recent Developments
  • Table 67. Travere Therapeutics Company Details
  • Table 68. Travere Therapeutics Business Overview
  • Table 69. Travere Therapeutics IgA Nephropathy Drugs Product
  • Table 70. Travere Therapeutics Revenue in IgA Nephropathy Drugs Business (2017-2022) & (US$ Million)
  • Table 71. Travere Therapeutics Recent Developments
  • Table 72. Omeros Corporation Company Details
  • Table 73. Omeros Corporation Business Overview
  • Table 74. Omeros Corporation IgA Nephropathy Drugs Product
  • Table 75. Omeros Corporation Revenue in IgA Nephropathy Drugs Business (2017-2022) & (US$ Million)
  • Table 76. Omeros Corporation Recent Developments
  • Table 77. Novartis International Company Details
  • Table 78. Novartis International Business Overview
  • Table 79. Novartis International IgA Nephropathy Drugs Product
  • Table 80. Novartis International Revenue in IgA Nephropathy Drugs Business (2017-2022) & (US$ Million)
  • Table 81. Novartis International Recent Developments
  • Table 82. Chinook Therapeutics Company Details
  • Table 83. Chinook Therapeutics Business Overview
  • Table 84. Chinook Therapeutics IgA Nephropathy Drugs Product
  • Table 85. Chinook Therapeutics Revenue in IgA Nephropathy Drugs Business (2017-2022) & (US$ Million)
  • Table 86. Chinook Therapeutics Recent Developments
  • Table 87. Vera Therapeutics Company Details
  • Table 88. Vera Therapeutics Business Overview
  • Table 89. Vera Therapeutics IgA Nephropathy Drugs Product
  • Table 90. Vera Therapeutics Revenue in IgA Nephropathy Drugs Business (2017-2022) & (US$ Million)
  • Table 91. Vera Therapeutics Recent Developments
  • Table 92. Otsuka Pharmaceutical Company Details
  • Table 93. Otsuka Pharmaceutical Business Overview
  • Table 94. Otsuka Pharmaceutical IgA Nephropathy Drugs Product
  • Table 95. Otsuka Pharmaceutical Revenue in IgA Nephropathy Drugs Business (2017-2022) & (US$ Million)
  • Table 96. Otsuka Pharmaceutical Recent Developments
  • Table 97. Research Programs/Design for This Report
  • Table 98. Key Data Information from Secondary Sources
  • Table 99. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Global IgA Nephropathy Drugs Market Share by Type: 2021 VS 2028
  • Figure 2. Phase I Features
  • Figure 3. Phase II Features
  • Figure 4. Phase III Features
  • Figure 5. Global IgA Nephropathy Drugs Market Share by Application: 2021 VS 2028
  • Figure 6. Clinical Treatment Case Studies
  • Figure 7. Drug Experiment Case Studies
  • Figure 8. IgA Nephropathy Drugs Report Years Considered
  • Figure 9. Global IgA Nephropathy Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
  • Figure 10. Global IgA Nephropathy Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 11. Global IgA Nephropathy Drugs Market Share by Region: 2021 VS 2028
  • Figure 12. Global IgA Nephropathy Drugs Market Share by Players in 2021
  • Figure 13. Global Top IgA Nephropathy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IgA Nephropathy Drugs as of 2021)
  • Figure 14. The Top 10 and 5 Players Market Share by IgA Nephropathy Drugs Revenue in 2021
  • Figure 15. North America IgA Nephropathy Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 16. North America IgA Nephropathy Drugs Market Size Market Share by Type (2017-2028)
  • Figure 17. North America IgA Nephropathy Drugs Market Size Market Share by Application (2017-2028)
  • Figure 18. North America IgA Nephropathy Drugs Market Size Share by Country (2017-2028)
  • Figure 19. United States IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 20. Canada IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 21. Europe IgA Nephropathy Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 22. Europe IgA Nephropathy Drugs Market Size Market Share by Type (2017-2028)
  • Figure 23. Europe IgA Nephropathy Drugs Market Size Market Share by Application (2017-2028)
  • Figure 24. Europe IgA Nephropathy Drugs Market Size Share by Country (2017-2028)
  • Figure 25. Germany IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 26. France IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 27. U.K. IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 28. Italy IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 29. Russia IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 30. Nordic Countries IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 31. Asia-Pacific IgA Nephropathy Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 32. Asia Pacific IgA Nephropathy Drugs Market Size Market Share by Type (2017-2028)
  • Figure 33. Asia Pacific IgA Nephropathy Drugs Market Size Market Share by Application (2017-2028)
  • Figure 34. Asia Pacific IgA Nephropathy Drugs Market Size Share by Region (2017-2028)
  • Figure 35. China IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 36. Japan IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 37. South Korea IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 38. Southeast Asia IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 39. India IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 40. Australia IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures

  • Figure 41. Latin America IgA Nephropathy Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 42. Latin America IgA Nephropathy Drugs Market Size Market Share by Type (2017-2028)
  • Figure 43. Latin America IgA Nephropathy Drugs Market Size Market Share by Application (2017-2028)
  • Figure 44. Latin America IgA Nephropathy Drugs Market Size Share by Country (2017-2028)
  • Figure 45. Mexico IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 46. Brazil IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 47. Middle East & Africa IgA Nephropathy Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 48. Middle East and Africa IgA Nephropathy Drugs Market Size Market Share by Type (2017-2028)
  • Figure 49. Middle East and Africa IgA Nephropathy Drugs Market Size Market Share by Application (2017-2028)
  • Figure 50. Middle East and Africa IgA Nephropathy Drugs Market Size Share by Country (2017-2028)
  • Figure 51. Turkey IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 52. Saudi Arabia IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 53. UAE IgA Nephropathy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 54. Calliditas Therapeutics Revenue Growth Rate in IgA Nephropathy Drugs Business (2017-2022)
  • Figure 55. Travere Therapeutics Revenue Growth Rate in IgA Nephropathy Drugs Business (2017-2022)
  • Figure 56. Omeros Corporation Revenue Growth Rate in IgA Nephropathy Drugs Business (2017-2022)
  • Figure 57. Novartis International Revenue Growth Rate in IgA Nephropathy Drugs Business (2017-2022)
  • Figure 58. Chinook Therapeutics Revenue Growth Rate in IgA Nephropathy Drugs Business (2017-2022)
  • Figure 59. Vera Therapeutics Revenue Growth Rate in IgA Nephropathy Drugs Business (2017-2022)
  • Figure 60. Otsuka Pharmaceutical Revenue Growth Rate in IgA Nephropathy Drugs Business (2017-2022)
  • Figure 61. Bottom-up and Top-down Approaches for This Report
  • Figure 62. Data Triangulation
  • Figure 63. Key Executives Interviewed
目次

This research report focuses on the IgA Nephropathy Drugs Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Report Business Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global IgA Nephropathy Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Phase I
    • 1.2.3 Phase II
    • 1.2.4 Phase III
  • 1.3 Market by Application
    • 1.3.1 Global IgA Nephropathy Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Clinical Treatment
    • 1.3.3 Drug Experiment
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global IgA Nephropathy Drugs Market Perspective (2017-2028)
  • 2.2 IgA Nephropathy Drugs Growth Trends by Region
    • 2.2.1 IgA Nephropathy Drugs Market Size by Region: 2017 VS 2021 VS 2028
    • 2.2.2 IgA Nephropathy Drugs Historic Market Size by Region (2017-2022)
    • 2.2.3 IgA Nephropathy Drugs Forecasted Market Size by Region (2023-2028)
  • 2.3 IgA Nephropathy Drugs Market Dynamics
    • 2.3.1 IgA Nephropathy Drugs Industry Trends
    • 2.3.2 IgA Nephropathy Drugs Market Drivers
    • 2.3.3 IgA Nephropathy Drugs Market Challenges
    • 2.3.4 IgA Nephropathy Drugs Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top IgA Nephropathy Drugs Players by Revenue
    • 3.1.1 Global Top IgA Nephropathy Drugs Players by Revenue (2017-2022)
    • 3.1.2 Global IgA Nephropathy Drugs Revenue Market Share by Players (2017-2022)
  • 3.2 Global IgA Nephropathy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Players Covered: Ranking by IgA Nephropathy Drugs Revenue
  • 3.4 Global IgA Nephropathy Drugs Market Concentration Ratio
    • 3.4.1 Global IgA Nephropathy Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by IgA Nephropathy Drugs Revenue in 2021
  • 3.5 IgA Nephropathy Drugs Key Players Head office and Area Served
  • 3.6 Key Players IgA Nephropathy Drugs Product Solution and Service
  • 3.7 Date of Enter into IgA Nephropathy Drugs Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 IgA Nephropathy Drugs Breakdown Data by Type

  • 4.1 Global IgA Nephropathy Drugs Historic Market Size by Type (2017-2022)
  • 4.2 Global IgA Nephropathy Drugs Forecasted Market Size by Type (2023-2028)

5 IgA Nephropathy Drugs Breakdown Data by Application

  • 5.1 Global IgA Nephropathy Drugs Historic Market Size by Application (2017-2022)
  • 5.2 Global IgA Nephropathy Drugs Forecasted Market Size by Application (2023-2028)

6 North America

  • 6.1 North America IgA Nephropathy Drugs Market Size (2017-2028)
  • 6.2 North America IgA Nephropathy Drugs Market Size by Type
    • 6.2.1 North America IgA Nephropathy Drugs Market Size by Type (2017-2022)
    • 6.2.2 North America IgA Nephropathy Drugs Market Size by Type (2023-2028)
    • 6.2.3 North America IgA Nephropathy Drugs Market Share by Type (2017-2028)
  • 6.3 North America IgA Nephropathy Drugs Market Size by Application
    • 6.3.1 North America IgA Nephropathy Drugs Market Size by Application (2017-2022)
    • 6.3.2 North America IgA Nephropathy Drugs Market Size by Application (2023-2028)
    • 6.3.3 North America IgA Nephropathy Drugs Market Share by Application (2017-2028)
  • 6.4 North America IgA Nephropathy Drugs Market Size by Country
    • 6.4.1 North America IgA Nephropathy Drugs Market Size by Country (2017-2022)
    • 6.4.2 North America IgA Nephropathy Drugs Market Size by Country (2023-2028)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe IgA Nephropathy Drugs Market Size (2017-2028)
  • 7.2 Europe IgA Nephropathy Drugs Market Size by Type
    • 7.2.1 Europe IgA Nephropathy Drugs Market Size by Type (2017-2022)
    • 7.2.2 Europe IgA Nephropathy Drugs Market Size by Type (2023-2028)
    • 7.2.3 Europe IgA Nephropathy Drugs Market Share by Type (2017-2028)
  • 7.3 Europe IgA Nephropathy Drugs Market Size by Application
    • 7.3.1 Europe IgA Nephropathy Drugs Market Size by Application (2017-2022)
    • 7.3.2 Europe IgA Nephropathy Drugs Market Size by Application (2023-2028)
    • 7.3.3 Europe IgA Nephropathy Drugs Market Share by Application (2017-2028)
  • 7.4 Europe IgA Nephropathy Drugs Market Size by Country
    • 7.4.1 Europe IgA Nephropathy Drugs Market Size by Country (2017-2022)
    • 7.4.2 Europe IgA Nephropathy Drugs Market Size by Country (2023-2028)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic Countries

8 Asia-Pacific

  • 8.1 Asia-Pacific IgA Nephropathy Drugs Market Size (2017-2028)
  • 8.2 Asia-Pacific IgA Nephropathy Drugs Market Size by Type
    • 8.2.1 Asia-Pacific IgA Nephropathy Drugs Market Size by Type (2017-2022)
    • 8.2.2 Asia-Pacific IgA Nephropathy Drugs Market Size by Type (2023-2028)
    • 8.2.3 Asia-Pacific IgA Nephropathy Drugs Market Share by Type (2017-2028)
  • 8.3 Asia-Pacific IgA Nephropathy Drugs Market Size by Application
    • 8.3.1 Asia-Pacific IgA Nephropathy Drugs Market Size by Application (2017-2022)
    • 8.3.2 Asia-Pacific IgA Nephropathy Drugs Market Size by Application (2023-2028)
    • 8.3.3 Asia-Pacific IgA Nephropathy Drugs Market Share by Application (2017-2028)
  • 8.4 Asia-Pacific IgA Nephropathy Drugs Market Size by Region
    • 8.4.1 Asia-Pacific IgA Nephropathy Drugs Market Size by Region (2017-2022)
    • 8.4.2 Asia-Pacific IgA Nephropathy Drugs Market Size by Region (2023-2028)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America IgA Nephropathy Drugs Market Size (2017-2028)
  • 9.2 Latin America IgA Nephropathy Drugs Market Size by Type
    • 9.2.1 Latin America IgA Nephropathy Drugs Market Size by Type (2017-2022)
    • 9.2.2 Latin America IgA Nephropathy Drugs Market Size by Type (2023-2028)
    • 9.2.3 Latin America IgA Nephropathy Drugs Market Share by Type (2017-2028)
  • 9.3 Latin America IgA Nephropathy Drugs Market Size by Application
    • 9.3.1 Latin America IgA Nephropathy Drugs Market Size by Application (2017-2022)
    • 9.3.2 Latin America IgA Nephropathy Drugs Market Size by Application (2023-2028)
    • 9.3.3 Latin America IgA Nephropathy Drugs Market Share by Application (2017-2028)
  • 9.4 Latin America IgA Nephropathy Drugs Market Size by Country
    • 9.4.1 Latin America IgA Nephropathy Drugs Market Size by Country (2017-2022)
    • 9.4.2 Latin America IgA Nephropathy Drugs Market Size by Country (2023-2028)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa IgA Nephropathy Drugs Market Size (2017-2028)
  • 10.2 Middle East & Africa IgA Nephropathy Drugs Market Size by Type
    • 10.2.1 Middle East & Africa IgA Nephropathy Drugs Market Size by Type (2017-2022)
    • 10.2.2 Middle East & Africa IgA Nephropathy Drugs Market Size by Type (2023-2028)
    • 10.2.3 Middle East & Africa IgA Nephropathy Drugs Market Share by Type (2017-2028)
  • 10.3 Middle East & Africa IgA Nephropathy Drugs Market Size by Application
    • 10.3.1 Middle East & Africa IgA Nephropathy Drugs Market Size by Application (2017-2022)
    • 10.3.2 Middle East & Africa IgA Nephropathy Drugs Market Size by Application (2023-2028)
    • 10.3.3 Middle East & Africa IgA Nephropathy Drugs Market Share by Application (2017-2028)
  • 10.4 Middle East & Africa IgA Nephropathy Drugs Market Size by Country
    • 10.4.1 Middle East & Africa IgA Nephropathy Drugs Market Size by Country (2017-2022)
    • 10.4.2 Middle East & Africa IgA Nephropathy Drugs Market Size by Country (2023-2028)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Calliditas Therapeutics
    • 11.1.1 Calliditas Therapeutics Company Details
    • 11.1.2 Calliditas Therapeutics Business Overview
    • 11.1.3 Calliditas Therapeutics IgA Nephropathy Drugs Introduction
    • 11.1.4 Calliditas Therapeutics Revenue in IgA Nephropathy Drugs Business (2017-2022)
    • 11.1.5 Calliditas Therapeutics Recent Developments
  • 11.2 Travere Therapeutics
    • 11.2.1 Travere Therapeutics Company Details
    • 11.2.2 Travere Therapeutics Business Overview
    • 11.2.3 Travere Therapeutics IgA Nephropathy Drugs Introduction
    • 11.2.4 Travere Therapeutics Revenue in IgA Nephropathy Drugs Business (2017-2022)
    • 11.2.5 Travere Therapeutics Recent Developments
  • 11.3 Omeros Corporation
    • 11.3.1 Omeros Corporation Company Details
    • 11.3.2 Omeros Corporation Business Overview
    • 11.3.3 Omeros Corporation IgA Nephropathy Drugs Introduction
    • 11.3.4 Omeros Corporation Revenue in IgA Nephropathy Drugs Business (2017-2022)
    • 11.3.5 Omeros Corporation Recent Developments
  • 11.4 Novartis International
    • 11.4.1 Novartis International Company Details
    • 11.4.2 Novartis International Business Overview
    • 11.4.3 Novartis International IgA Nephropathy Drugs Introduction
    • 11.4.4 Novartis International Revenue in IgA Nephropathy Drugs Business (2017-2022)
    • 11.4.5 Novartis International Recent Developments
  • 11.5 Chinook Therapeutics
    • 11.5.1 Chinook Therapeutics Company Details
    • 11.5.2 Chinook Therapeutics Business Overview
    • 11.5.3 Chinook Therapeutics IgA Nephropathy Drugs Introduction
    • 11.5.4 Chinook Therapeutics Revenue in IgA Nephropathy Drugs Business (2017-2022)
    • 11.5.5 Chinook Therapeutics Recent Developments
  • 11.6 Vera Therapeutics
    • 11.6.1 Vera Therapeutics Company Details
    • 11.6.2 Vera Therapeutics Business Overview
    • 11.6.3 Vera Therapeutics IgA Nephropathy Drugs Introduction
    • 11.6.4 Vera Therapeutics Revenue in IgA Nephropathy Drugs Business (2017-2022)
    • 11.6.5 Vera Therapeutics Recent Developments
  • 11.7 Otsuka Pharmaceutical
    • 11.7.1 Otsuka Pharmaceutical Company Details
    • 11.7.2 Otsuka Pharmaceutical Business Overview
    • 11.7.3 Otsuka Pharmaceutical IgA Nephropathy Drugs Introduction
    • 11.7.4 Otsuka Pharmaceutical Revenue in IgA Nephropathy Drugs Business (2017-2022)
    • 11.7.5 Otsuka Pharmaceutical Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Author Details
  • 13.3 Disclaimer